6 patents
Utility
Methods of Administering Genetically Modified B Cells for In Vivo Delivery of Therapeutic Agents
28 Dec 23
Provided herein are methods for administering engineered B cells to produce a therapeutic agent in vivo.
Christiane S. HAMPE
Filed: 29 Oct 21
Utility
B Cells for In Vivo Delivery of Therapeutic Agents
16 Mar 23
The present disclosure relates to genetically modified B cells, including memory cells, differentiated to plasmablasts or plasma cells useful for long term in vivo expression of a transgene, such as a specific antibody or other protein therapeutic.
Matthew Rein SCHOLZ, Eric J. HERBIG, Mei XU, Rian DE LAAT
Filed: 11 Aug 22
Utility
Methods for In Vitro Memory B Cell Differentiation and Transduction with VSV-G Pseudotyped Viral Vectors
19 Jan 23
The present disclosure relates to the in vitro differentiation of memory B cells to plasmablasts or plasma cells and genetic modification of these cells to express a protein of interest, such as a specific antibody or other protein therapeutic.
Mei XU, Matthew Rein SCHOLZ, Eric J. HERBIG
Filed: 3 May 22
Utility
B Cells for In Vivo Delivery of Therapeutic Agents and Dosages Thereof
23 Jun 22
The present invention relates to methods for administering autologous and/or allogeneic B cells genetically modified to produce a therapeutic agent, such as a therapeutic protein.
Matthew Rein Scholz, Eric J. HERBIG, R. Scott MCIVOR, Rian DE LAAT, Erik Olson
Filed: 27 Apr 18
Utility
B Cells Genetically Engineered to Secrete Follistatin and Methods of Using the Same to Treat Follistatin-related Diseases, Conditions, Disorders and to Enhance Muscle Growth and Strength
18 Feb 21
The present invention relates to methods for administering autologous and/or allogeneic B cells genetically modified to produce a therapeutic agent, such as follistatin.
Matthew Rein SCHOLZ, Eric J. HERBIG, R. Scott MCIVOR
Filed: 18 Mar 19
Utility
Chimeric Antigen Receptors Specific to AVB6 Integrin and Methods of Use Thereof to Treat Cancer
20 May 20
Disclosed are chimeric antigen receptors (CAR) specific to αvβ6 integrin which is uniquely expressed in a wide variety of cancers.
R. Scott MCIVOR, Kendra A. HYLAND
Filed: 3 Jun 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first